Haemophilia treatment for all: A partnership for better access
:quality(90)/)
The Humanitarian Aid Program, a landmark initiative led by the World Federation of Hemophilia (WFH) and supported by partners including Roche, is working to ensure that people with bleeding disorders in developing countries can access the diagnosis, treatment and care they need.
Haemophilia A affects approximately 900,000 people worldwide, and can significantly reduce the quality of life of people affected, as well as that of their family, friends, and caregivers.
Most people with bleeding disorders in low-to-middle income countries have very little access to diagnosis, treatment and care, which significantly impacts their health, quality of life and life expectancy1 Because of this, children and adults who have haemophilia face an uncertain future.
Medical care for haemophilia A, perhaps the most well-known inherited bleeding disorder, is often restricted in developing countries. Resources are limited and saved for emergency situations or isolated bleeding events and cannot always be used for prolonged protection against bleeding episodes. This means people with haemophilia A, especially those with inhibitors, where treatment options are particularly limited, often suffer painful joint bleeds which could significantly affect their health and quality of life.
We believe that even one bleed is one too many, especially in a condition like haemophilia A that is for life, and the management of the disease in the first five years of life is particularly crucial in determining its long-term impact. People with severe haemophilia in these countries often do not survive to adulthood because they are unable to access the treatment that they so critically need.2 For those who do, life often entails severe disability, isolation and chronic pain.
In addition, these bleeding episodes impact the quality of life for these patients and their caregivers, for the duration of their lifetime; resulting in missed school, work, physical or social activities with friends and family. In fact, for people born with haemophilia in low-income countries, the chances of living a normal lifespan are reduced by up to 93%.3
The WFH is leading the effort to change this. Through the WFH Humanitarian Aid Program, the organisation is working with multiple partners, including Roche, to provide consistent and predictable access to preventative and on-demand treatment for bleeding disorders.
The WFH Humanitarian Aid Program continues to support our goal of improving the quality of life for people with bleeding disorders by increasing diagnosis and treatment numbers. With the Program, we are able to work towards our vision of Treatment for All by providing sustainable access treatment, including novel therapies for emergency and preventative treatment.
:quality(90)/)
Why is prophylactic treatment important for people with haemophilia A?
Prophylaxis, the regular use of treatment to prevent bleeds before they happen, allows people with severe haemophilia to remain active and participate more fully in daily life.
In addition to providing donated prophylactic treatments to those in need, the Program also highlights the benefit of prophylaxis to show governments how sustainable care can ultimately benefit their society as a whole, for example, by increasing participation in school and work.
The lack of access to adequate care and treatment available for people with inherited bleeding disorders, such as haemophilia, in developing countries can have a devastating effect on their lives, both physically and psychosocially. Through the Program, donations are increasingly used to treat young people prophylactically; allowing them to go to school and social events, and generally leading to fewer bleeds, less joint damage, and a more normal life.
What has Roche contributed to the WFH Humanitarian Aid Program?
Since 2019, Roche has been a Visionary Contributor to the WFH Humanitarian Aid Program. So far, Roche has provided its novel prophylactic treatment to over 1,220 people with haemophilia A in 36 countries where there is little or no access to haemophilia treatment.
The partnership marked the first time that people with haemophilia A in developing countries had received access to a subcutaneous prophylactic treatment that can be administered as infrequently as once per month. Roche’s support of the WFH Humanitarian Aid Program also extends to the programme’s integrated care development training, to ensure that locally, the medical expertise is available to optimise and appropriately use donated therapy.
What drives our support for the Humanitarian Aid Program is the belief that access to consistent care shouldn’t depend on where someone lives. Our partnership with the World Federation of Hemophilia reflects a long-term commitment to improving access in low- and middle-income countries and helping people live more active, less restricted lives. By supporting full-dose prophylaxis and strengthening local systems, we aim to help countries build predictable, sustainable care that will serve people for generations.
How is the WFH Humanitarian Aid Program changing lives in Zambia?
By working toward a shared vision of Treatment for All, the WFH and all of its partners, including Roche, are aiming to address gaps in care and enable people with a high need for treatment to experience an improved quality of life and longer-term protection against bleeding episodes.
For more information on the work of the Humanitarian Aid Program in Zambia, see this video on the WFH YouTube channel: https://www.youtube.com/watch?v=Dm5ViUJw11k
Main Highlights
Since 2019, Roche has been a Visionary Contributor to the WFH Humanitarian Aid Program. So far, Roche has provided its novel prophylactic treatment to over 1,220 people with haemophilia A in 36 countries where there is little or no access to haemophilia treatment.
References
World Federation of Hemophilia. Achieving Global Impact Strategic Plan: 2021-2025 [Internet; cited April 2026]. Available from: https://wfh.org/wp-content/uploads/2021/12/WFH-Strategic-Plan-2021-2025.pdf [Last accessed April 2021]
Ghosh K and Ghosh K. Management of haemophilia in developing countries: challenges and options. Indian J Hematol Bloos Transfus. 2016 July-Sept; 32(3):347-355.
Iorio A, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males. Ann Intern Med. 2019;171(8):540. doi:10.7326/m19-1208
About The WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)